1345822-87-8 Usage
Description
Sitagliptin EP Impurity B is a compound related to Sitagliptin, a medication used for the treatment of type II diabetes. It is an impurity found in the Sitagliptin phosphate formulation and is characterized by its chemical structure and properties.
Uses
Used in Pharmaceutical Industry:
Sitagliptin EP Impurity B is used as a reference material for the development and quality control of Sitagliptin pharmaceutical products. It helps ensure the purity, safety, and efficacy of Sitagliptin in the treatment of type II diabetes.
Used in Research and Development:
Sitagliptin EP Impurity B serves as an important compound in the research and development of new drugs and therapies for type II diabetes. It aids in understanding the mechanisms of action, potential side effects, and interactions with other medications.
Used in Metabolite Studies:
As a metabolite of Sitagliptin phosphate, Sitagliptin EP Impurity B is used in studies to understand the metabolic pathways and pharmacokinetics of Sitagliptin in the body. This information is crucial for optimizing drug dosages and minimizing adverse effects.
Used in Drug Regulatory Compliance:
Sitagliptin EP Impurity B is utilized in the assessment of compliance with regulatory standards for pharmaceutical manufacturing. It helps ensure that the Sitagliptin pharmaceutical products meet the required quality and safety guidelines.
Check Digit Verification of cas no
The CAS Registry Mumber 1345822-87-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,4,5,8,2 and 2 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1345822-87:
(9*1)+(8*3)+(7*4)+(6*5)+(5*8)+(4*2)+(3*2)+(2*8)+(1*7)=168
168 % 10 = 8
So 1345822-87-8 is a valid CAS Registry Number.
1345822-87-8Relevant articles and documents
SITAGLIPTIN, SALTS AND POLYMORPHS THEREOF
-
Paragraph 0178; 0179; 0180; 181; 0195; 0196, (2013/06/28)
The present invention relates to an improved process for preparation of Sitagliptin or pharmaceutically acceptable salts thereof. The present invention further relates to novel polymorphs of Sitagliptin salts and process for preparation thereof.
